Examining New Treatment Strategies Aimed at Stroke Prevention in Patients with Atrial Fibrillation: A Multidisciplinary Discussion

Jennifer Costello, PharmD, BCPS, BC-ADM; Mindy Houng, MD, FACP; and Steven J. Sheris, MD, FACC, FACP
Published Online: Monday, March 17, 2014
Follow Pharmacy_Times:
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Examining New Treatment Strategies Aimed at Stroke Prevention in Patients with Atrial Fibrillation: A Multidisciplinary Discussion

Jennifer Costello, PharmD, BCPS, BC-ADM
Ambulatory Clinical Pharmacist
Internal Medicine Faculty Pharmacist
Saint Barnabas Medical Center
Livingston, New Jersey
 
Mindy Houng, MD, FACP
Associate Program Director
Internal Medicine Residency Program
Department of Medicine
Saint Barnabas Medical Center
Livingston, New Jersey
Clinical Assistant Professor
Department of Medicine
Rutgers University, New Jersey
Medical School
Newark, New Jersey
 
Steven J. Sheris, MD, FACC, FACP
Chief of Cardiology
Overlook Medical Center
Gagnon Cardiovascular Institute
Summit, New Jersey
 
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose
 
Faculty
Jennifer Costello, PharmD, BCPS, BC-ADM
Mindy Houng, MD, FACP
Steven J. Sheris, MD, FACC, FACP

Pharmacy Times Office of Continuing Professional Education
Planning StaffDavid Heckard; Steve Lin, PharmD, RPh; Maryjo Dixon, RPh; and Donna Fausak
 
Pharmacy Times
Editorial StaffBea Riemschneider and Kirk McKay

An anonymous peer reviewer was part of the content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Objective
At the conclusion of this educational activity, participants should be able to:
  • Discuss the prevalence, epidemiology, and risk of stroke in patients with atrial fibrillation (AF).
  • Explore the underrecognized risk of stroke and inadequate prophylaxis in patients with AF.
  • Examine current guidelines, with respect to risk stratification recommendations for appropriate anticoagulation, and impact on patient outcomes.
  • Review newly approved oral anticoagulants and identify their practice-focused differences from warfarin and their role in stroke prevention.
  • Explore the pharmacist’s role in educating patients on the risk of stroke in AF, monitoring anticoagulation therapy, and participating in disease management opportunities.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: March 12, 2014
Expiration date: March 12, 2016
Estimated time to complete activity: 2 hours
Fee: Free

Click here to view this activity.
 
Description: Pharmacy Times/Ascend Media Office of Continuing Professional EducationPharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-14-015-H01-P. The activity is available for CE credit through March 12, 2016.

Related Articles
As the 2015 American College of Cardiology Annual Scientific Session and Expo concludes, take a look at a few of the latest discoveries that were presented at the conference.
Warfarin has been used for over half a century, and its interactions with other drugs have been exhaustively investigated.
The new target-specific oral anticoagulants, which include dabigatran, rivaroxaban, apixaban, and edoxaban have demonstrated safety and efficacy in the treatment of venous thromboembolism.
Labels of prescription testosterone products must now include information about possible cardiovascular and stroke risks associated with their use.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$